Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway
Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeabi...
